Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Goldfinch Biopharma

Request full access

Singularly focused on discovering and developing precision therapies for patients with kidney disease

Cambridge, United StatesFounded 2016Biotech & Life Sciences

About Goldfinch Biopharma

Goldfinch Bio is a biotechnology company focused on developing precision therapies for patients with kidney diseases, particularly those with genetic origins. The company leverages advanced genomic data and cutting-edge research to identify and treat subgroups of patients with specific genetic markers. Operating in the biopharmaceutical sector, Goldfinch Bio primarily serves patients suffering from rare and complex kidney conditions. Its business model revolves around the research and development of novel drugs, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships with other biotech firms, and potential licensing agreements. The company aims to transform the lives of patients by providing targeted treatments that address the underlying genetic causes of kidney diseases.

Source: Dealroom company data

At a glance

Status
Closed
Employees
5
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, DNA, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2020 $100M $400M Wellington Management · Casdin Capital · Schroder Adveq · Gilead Sciences —
SERIES AOther financing Dec 2016 $55M $220M Third Rock Ventures —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Goldfinch Biopharma website traffic

Latest recorded traffic for Goldfinch Biopharma is 200 monthly website visits, down 81.8% over the last three months. Goldfinch Biopharma's team declined 28.6% over the past year.

Latest monthly visits200 3-month web change-81.8% 1-year team growth-28.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Goldfinch Biopharma in the Cambridge ecosystem

Live from Dealroom

The Goldfinch Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Goldfinch Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Goldfinch Biopharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.